Recruiting
B-cell small lymphocytic lymphoma refractory+1
RecruitingStudy of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Registered drugNo placebo
Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Registered drugNo placebo
- Disease:B-cell small lymphocytic lymphoma refractoryB-cell small lymphocytic lymphoma recurrent
- Substances:ObinutuzumabRituximab+2
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab
- Sponsor:BeOne Medicines AG



